Clinical trials: Hematopoietic
Aplastic Anemias
Umbilical Cord Blood-Supported Haplo-HSCT for Aplastic Anemia Treatment Study
Aplastic anemia (AA) is a rare bone marrow failure syndrome with an annual incidence of about 0.74/100,000, affecting all ages but more common in the elderly.
- Trial name
- NCT06650553
- Testing
- Clinically diagnosed AA patients are divided into HLA-matched HSCT group and umbilical cord blood-supported haplo-HSCT group.
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Shanxi Bethune Hospital
Cerebral Toxoplasmosis
Study of a Cohort of Non-HIV Immunocompromised Patients With Toxoplasmosis at the Strasbourg University Hospital
Toxoplasmosis in HIV-positive individuals is well-studied and has a codified management protocol, which is not the case for other immunodeficiencies, except for recent recommendations in the context of hematopoietic stem cell…
- Trial name
- TOXO (NCT07299500)
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Strasbourg, France
Multiple Sclerosis
Randomized Autologous heMatopoietic Stem Cell Transplantation Versus Alemtuzumab, Cladribine or Ocrelizumab for RRMS (RAM-MS)
This study is a randomized multicentre, multinational, treatment interventional study of RRMS patients with breakthrough inflammatory disease activity in spite of ongoing standard immunomodulatory medication.
- Trial name
- RAM-MS (NCT03477500)
- Testing
- Cyclophosphamide and ATG, Alemtuzumab, Cladribine Pill
- Where
- 8 sites in Denmark, Netherlands and 2 more
- Volunteers
- 100 people
- Sponsor
- Haukeland University Hospital
Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Neoplasm
Outreach Project to Connect Underrepresented Populations to Clinical Trials at Ohio State University, CUSP2CT Project Trial
This clinical trial tests the impact of the The Ohio State University Connecting Underrepresented Populations to Clinical Trials (CUSP2CT) project on clinical trial referrals and enrollment in racial/ethnic minorities.
- Trial name
- NCT06314672
- Testing
- Accrual, Discussion, Educational Activity
- Where
- United States
- Volunteers
- 208 people, healthy volunteers welcome
- Sponsor
- Ohio State University Comprehensive Cancer Center
Allogeneic Hematopoietic Stem Cell Transplantation
Dose Finding Study of Vedolizumab for GvHD in Participants Undergoing Allogeneic HSCT
The purpose of this study is to assess the initial tolerability, safety and recommended phase 2 dose of vedolizumab intravenous (IV) administered for GvHD prophylaxis along with standard GvHD prophylaxis therapy (in participants…
- Trial name
- NCT02728895
- Testing
- Vedolizumab
- Where
- 5 sites in United States
- Volunteers
- 24 people
- Sponsor
- Takeda
Allogeneic Hematopoietic Stem Cell Transplantation, Allogeneic Stem Cell Transplantation
Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation
This is a prospective, single-arm, phase II study. Patients will be treated with an allogeneic stem cell transplantation (AHSCT) using fludarabine, melphalan and total body irradiation (TBI) conditioning with different melphalan…
- Conditions
- Allogeneic Hematopoietic Stem Cell Transplantation, Allogeneic Stem Cell Transplantation, Hematologic Malignancies
- Trial name
- ADAPT (NCT06028828)
- Testing
- Fludarabine, Melphalan, Total Body Irradiation
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of California, Irvine
Acute Leukemia, MDS
Assessment of Measurable Residual Disease in Allo-HSCT Using Digital Polymerase Chain Reaction
A research investigation into the efficacy of digital Polymerase Chain Reaction (dPCR) for monitoring measurable residual disease (MRD) during allogeneic hematopoietic stem cell transplantation, with a focus on predicting relapse…
- Conditions
- Acute Leukemia, MDS, MDS/MPN, CML
- Trial name
- NCT06211166
- Testing
- Digital PCR, Quantitative PCR, MFC
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Peking University People's Hospital
Malignant Neoplasm
Resistance Training Program and Cardiovascular Exercise in Increasing Muscle Mass in Adolescent and Young Adult Stem Cell Transplant Survivors
This pilot trial studies how well a resistance training program and cardiovascular exercise work in increasing muscle mass in adolescent and young adult stem cell transplant survivors.
- Trial name
- NCT03672981
- Testing
- Exercise Intervention, Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Fred Hutchinson Cancer Center
Hematopoietic/Lymphoid Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Alvocidib in Treating Patients With Metastatic or Unresectable Refractory Solid Tumors or Hematologic Malignancies
This phase I trial is studying the side effects and best dose of alvocidib in treating patients with metastatic or unresectable refractory solid tumors or hematologic malignancies.
- Trial name
- NCT00070239
- Testing
- alvocidib, pharmacological study, fludeoxyglucose F 18
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Myeloproliferative Disorders, Leukemia
Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen
RATIONALE: Giving chemotherapy, such as fludarabine and busulfan, before a donor peripheral stem cell transplant helps stop the growth of cancer or abnormal cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- LCCC0510 (NCT00448357)
- Testing
- rabbit anti-thymocyte globulin (ATG), therapeutic allogeneic lymphocytes, busulfan
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
To Evaluate the Efficacy and Safety of Secondary Prophylaxis of CMV Reactivation
Secondary Prophylaxis of CMV Infection Using Letermovir After HID-HSCT
To evaluate the efficacy and safety of secondary prophylaxis of CMV reactivation, clinically significant CMV infection with oral letermovir in Chinese haplo-HSCT patients, as well as treatment-related mortality, all-cause…
- Trial name
- NCT05914701
- Testing
- Letermovir for secondary prophylaxis
- Volunteers
- 31 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Patients Who Have Received Allo-HSCT
Imatinib for Cytomegalovirus Prophylaxis and Treatment After Allogeneic Hematopoietic Stem Cell Transplantation
This study aim at examining whether blocking platelet-derived growth factor receptor-α by imatinib lowers the risk of post-allogeneic hematopoietic stem cell transplantation CMV infection.
- Trial name
- NCT03343600
- Testing
- Imatinib
- Where
- 5 sites in Taiwan
- Volunteers
- 5 people
- Sponsor
- National Taiwan University Hospital
Atherosclerosis, Cardiovascular Diseases
The Role of Stem Cells on Immune Cells in the Development of Cardiovascular Diseases
An observational pilot proof-of-principle study. 15 patients with significant coronary artery disease and 15 matched controls. To investigate whether long-term activation of the innate immune system, named 'trained innate…
- Trial name
- ATHEROSTEM (NCT03172507)
- Where
- 2 sites in Netherlands
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Cytomegalovirus Infections, Adenovirus Infection
Antiviral Cellular Therapy for Enhancing T-cell Reconstitution Before or After Hematopoietic Stem Cell Transplantation
The purpose of this study is to evaluate whether virus-specific T cell lines (VSTs) are safe and can effectively control three viruses (EBV, CMV, and adenovirus) in patients who have had a stem cell transplant and also in…
- Conditions
- Cytomegalovirus Infections, Adenovirus Infection, EBV Infection
- Trial name
- ACES (NCT03475212)
- Testing
- Virus Specific T-cell (VST) infusion
- Where
- 30 sites in United States
- Volunteers
- 52 people
- Sponsor
- Pediatric Transplantation & Cellular Therapy Consortium
Viral Infection After HSCT
Adoptive T-cell Therapy for Resistant Viral Infections After Allogeneic HSCT
The aim of the study is to evaluate the adverse events and the efficacy of virus specific T lymphocytes selected in vitro from a family donor to treat some refractory viral infections as Adenovirus (ADV), Ebstein Barr virus…
- Trial name
- VS-TC (NCT05075837)
- Testing
- Virus -specific T cells
- Volunteers
- 10 people
- Sponsor
- Istituto Giannina Gaslini
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory Pneumonitis
This phase II trial studies how well infliximab and intravenous immunoglobulin therapy work in treating patients with pneumonitis that does not respond to steroid treatment.
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Steroid-Refractory Pneumonitis
- Trial name
- NCT04438382
- Testing
- Infliximab, Intravenous Immunoglobulin Therapy, Prednisone
- Where
- 18 sites in United States
- Volunteers
- 1 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Myelofibrosis, High-Risk Cancer
Study of Stem Cell Transplant vs. Non-Transplant Therapies in High-Risk Myelofibrosis
The purpose of this research study is to see how effective hematopoietic stem cell transplantation (HCT) is compared to best available non-transplant therapies (BAT) in patients with high risk myelofibrosis.
- Conditions
- Myelofibrosis, High-Risk Cancer, Bone Marrow Cancer
- Trial name
- ALLO-BAT (NCT04217356)
- Testing
- Hematopoietic stem cell transplant, Ruxolitinib, Hydroxyurea
- Where
- 5 sites in Canada
- Volunteers
- 90 people
- Sponsor
- University Health Network, Toronto
Older Patients, Myeloid Malignancies
VEN+DAC+Bu2Flu4 vs Bu2Flu5 Conditioning Regimen for Elderly Myeloid Malignancies Undergoing Allo-HSCT
The purpose of this study is to compare the efficacy and safety of venetoclax+decitabine+busulfan+fludarabine (VEN+DAC+Bu2Flu4) regimen with busulfan+fludarabine (Bu2Flu5) regimen in older patients with myeloid malignancies…
- Conditions
- Older Patients, Myeloid Malignancies, Conditioning, Hematopoietic Stem Cell Transplantation (HSCT)
- Trial name
- NCT07052422
- Testing
- Venetoclax (VEN), Decitabine (DAC), Busulfan (Bu)
- Volunteers
- 160 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Bone Marrow Failure Syndrome, Thalassemia
Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation
In this study, the investigators test 2 dose levels of thiotepa (5 mg/kg and 10 mg/kg) added to the backbone of targeted reduced dose IV busulfan, fludarabine and rabbit anti-thymocyte globulin (rATG) to determine the minimum…
- Conditions
- Bone Marrow Failure Syndrome, Thalassemia, Sickle Cell Disease, Diamond Blackfan Anemia
- Trial name
- NCT03513328
- Testing
- Thiotepa--single daily dose, Thiotepa--escalated dose
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Florida
COVID-19, COVID-19 (SARS-CoV-2 Infection)
Evaluation of Safety, Tolerance, and Efficacy of Allogeneic LB-DTK-COV19 in Severe Coronavirus Disease 2019 Patients
The goal of this clinical trial is to evaluate the safety, tolerability, and efficacy of allogeneic SARS-CoV-2-Specific T cells (LB-DTK-COV19) in patients with persistent clinical symptoms following a positive SARS-CoV-2 PCR test…
- Trial name
- NCT07709637
- Testing
- LB-DTK-COV19
- Where
- South Korea
- Volunteers
- 1 people
- Sponsor
- LucasBio
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.